Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R. S., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G. M., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 916 · see citing works

axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.

O’Bryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C. A., Espinosa, R., Beau, M. M. L., Earp, H. S., & Liu, E. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5016 · Cited by 746 · see citing works

Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance

Arpino, G., Weiss, H. L., Lee, A. V., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji249 · Cited by 485 · see citing works

Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6

Varnum, B. C., Young, C., Elliott, G., Garcia, A., Bartley, T. D., Fridell, Y.-W. C., Hunt, R. W., Trail, G., Clogston, C., Toso, R. J., et al. (1995) · Nature · doi:10.1038/373623a0 · Cited by 482 · see citing works

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374 · see citing works

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

Ryan, Q. C., Ibrahim, A., Cohen, M. H., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0816 · Cited by 307 · see citing works

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S., Robell, K. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 298 · see citing works

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

Mahadevan, D., Cooke, L. S., Riley, C., Swart, R. E., Simons, B. W., Croce, K. D., Wisner, L., Iorio, M. V., Shakalya, K., Garewal, H. S., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210173 · Cited by 283 · see citing works

Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

Hutterer, M., Knyazev, P. G., Abate, A., Reschke, M., Maier, H., Stefanova, N., Knyazeva, T., Barbieri, V., Reindl, M., Muigg, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0862 · Cited by 281 · see citing works

Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression

Shinh, Y.-S., Lai, C.-Y., Kao, Y.-R., Shiah, S., Chu, Y., Lee, H., & Wu, C. (2005) · Neoplasia · doi:10.1593/neo.05640 · Cited by 274 · see citing works

Targeting HER proteins in cancer therapy and the role of the non-target HER3

Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269 · see citing works

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267 · see citing works

Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases

Hafizi, S., & Dahlbäck, B. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.004 · Cited by 261 · see citing works

A novel putative tyrosine kinase receptor with oncogenic potential.

Janssen, J. W. G., Schulz, A. S., Steenvoorden, A. C. M., Schmidberger, M., Strehl, S., Ambros, P. F., & Bartram, C. R. (1991) · PubMed · Cited by 254 · see citing works

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

Hong, C., Lay, J., Huang, J.-S., Cheng, A., Tang, J., Lin, M., Lai, G., & Chuang, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.017 · Cited by 234 · see citing works

axl , a Transforming Gene Isolated from Primary Human Myeloid Leukemia Cells, Encodes a Novel Receptor Tyrosine Kinase

O’Bryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C. A., Espinosa, R., Beau, M. M. L., Earp, H. S., & Liu, E. T. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5016-5031.1991 · Cited by 232 · see citing works

Phosphoproteomic analysis of Her2/neu signaling and inhibition

Bose, R., Molina, H., Patterson, A., Bitok, J. K., Periaswamy, B., Bader, J. S., Pandey, A., & Cole, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603948103 · Cited by 215 · see citing works

AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression

Zhang, Y., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Őrfi, L., Szabadkai, I., Daub, H., Kéri, G., & Ullrich, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2661 · Cited by 214 · see citing works

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

Han, E. K.-H., Leverson, J. D., McGonigal, T. P., Shah, O. J., Woods, K. W., Hunter, T. R., Giranda, V. L., & Luo, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210343 · Cited by 169 · see citing works

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines

Rusnak, D. W., Alligood, K. J., Mullin, R. J., et al. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00455.x · Cited by 168 · see citing works

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Fujita, T., Doihara, H., Kawasaki, K., Takabatake, D., Takahashi, H., Washio, K., Tsukuda, K., Ogasawara, Y., & Shimizu, N. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602926 · Cited by 156 · see citing works

Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer

MacLeod, K. G., Mullen, P., Sewell, J. M., Rabiasz, G. J., Lawrie, S. S., Miller, E. P., Smyth, J. F., & Langdon, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2684 · Cited by 152 · see citing works

Receptor tyrosine kinases expressed in metastatic colon cancer

Craven, R. J., Xu, L., Weiner, T. M., Fridell, Y.-W. C., Dent, G. A., Srivastava, S., Varnum, B. C., Liu, E. T., & Cance, W. G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600611 · Cited by 146 · see citing works

ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase

Hellyer, N. J., Cheng, K., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3330757 · Cited by 144 · see citing works

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston, S. R. D., Head, J. E., Pancholi, S., DETRE, S. I., Martin, L., Smith, I. E., & Dowsett, M. (2003) · PubMed · Cited by 138 · see citing works

Overexpression of Protein Tyrosine Kinases in Human Esophageal Cancer

Nemoto, T., Ohashi, K., Akashi, T., et al. (2008) · Pathobiology · doi:10.1159/000164123 · Cited by 131 · see citing works

Sulfasalazine Suppresses Drug Resistance and Invasiveness of Lung Adenocarcinoma Cells Expressing AXL

Lay, J., Hong, C., Huang, J.-S., Yang, Y.-Y., Pao, C.-Y., Liu, C.-H., Lai, Y.-P., Lai, G., Cheng, A., Su, I., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3191 · Cited by 114 · see citing works

Clinical significance of AXL kinase family in gastric cancer.

Wu, C.-W., Li, A. F., Chi, C., et al. (2002) · PubMed · Cited by 107 · see citing works

Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast

Berclaz, G., Altermatt, H. J., Rohrbach, V., Kieffer, I., Dreher, E. F., & Andres, A. ‐. (2001) · Annals of Oncology · doi:10.1023/a:1011126330233 · Cited by 107 · see citing works

Coexpression of Gas6/Axl in Human Ovarian Cancers

Sun, W.-S., Fujimoto, J., & Tamaya, T. (2004) · Oncology · doi:10.1159/000079499 · Cited by 105 · see citing works

The human receptor tyrosine kinase Axl gene – promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation

Mudduluru, G., & Allgayer, H. (2008) · Bioscience Reports · doi:10.1042/bsr20080046 · Cited by 96 · see citing works

Lapatinib and IGF-I signaling

(2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-11-cor3 · Cited by 91 · see citing works

Expression of the Axl Receptor Tyrosine Kinase in Human Thyroid Carcinoma

ITO, T., Ito, M., Naito, S., et al. (1999) · Thyroid · doi:10.1089/thy.1999.9.563 · Cited by 81 · see citing works

Expression of the Proto-Oncogene Axl in Renal Cell Carcinoma

Chung, B. I., Malkowicz, S. B., Nguyen, T. B., et al. (2003) · DNA and Cell Biology · doi:10.1089/10445490360708946 · Cited by 74 · see citing works

Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial.

Johnston, S. R. D., Pegram, M. D., Press, M. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-46 · Cited by 66 · see citing works

Determinants for transformation induced by the Axl receptor tyrosine kinase

Burchert, A., Attar, E. C., McCloskey, P., Fridell, Y.-W. C., & Liu, E. T. (1998) · Oncogene · doi:10.1038/sj.onc.1201865 · Cited by 65 · see citing works

Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

Johnston, S. R. D., Martin, L., Head, J. E., et al. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.004 · Cited by 63 · see citing works

In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; <i>in vitro</i> mutagenesis defines the requisite binding sites for downstream Akt activation

Weinger, J. G., Gohari, P., Yan, Y., Backer, J. M., Varnum, B., & Shafit‐Zagardo, B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05343.x · Cited by 58 · see citing works

PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).

Migliaccio, I., Gutiérrez, M. T., Wu, M., Wong, H., Pavlick, A. C., Hilsenbeck, S., Horlings, H. M., Rimawi, M., Berns, K., Bernards, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-34 · Cited by 30 · see citing works

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · see citing works

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604 · see citing works

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325 · see citing works

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

Wilson, C., Ye, X., Pham, T., Lin, E., Chan, S., McNamara, E., Neve, R. M., Belmont, L., Koeppen, H., Yauch, R. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1009 · Cited by 150 · see citing works

Regulation of efferocytosis as a novel cancer therapy

Zhou, Y., Yao, Y., Deng, Y., & Shao, A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00542-9 · Cited by 100 · see citing works

A systematic study on drug-response associated genes using baseline gene expressions of the cancer cell line encyclopedia

Liu, X., Yang, J., Zhang, Y., Fang, Y., Wang, F., Wang, J., Zheng, X., & Yang, J. (2016) · Scientific Reports · doi:10.1038/srep22811 · Cited by 63 · see citing works

Lapatinib: A competitor or companion to trastuzumab?

Collins, D. C., Hill, A. D. K., & Young, L. S. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.06.002 · Cited by 8 · see citing works

Abstract 613: Increased PI3K/AKT activity, which confers resistance to trastuzumab, can be overcome by lapatinib

O’Brien, N. A., Wang, Y., Chow, L., Wilcox, K., Browne, B. C., Crown, J. P., Arboleda, J., Ginther, C., Duffy, M. J., O’Donovan, N., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-613

Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer

Hoyle, B. D., & Piccart, M. J. (2014) · MD Conference Express · doi:10.1177/155989771414007

Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.

Jia, W., & Wang, T. Z. (2019) · PubMed · Cited by 1 · see citing works

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Scaltriti, M., Nuciforo, P. G., Bradbury, I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1824 · Cited by 105 · see citing works